Marinomed Biotech Announces Capital increase with subscription rights
Ad-hoc: Marinomed Biotech AG has decided to conduct a cash capital increase to cover short-term capital requirements of approximately EUR 2 million
Ad-hoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Marinomed Biotech AG announces results for the first half year of 2025
Public Relations